Search Within

Chrisann Kyi Kyi

  1. "2022"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (2)
Groups
  1. Department of Medicine (8)
  2. GDMT, Medicine (8)
  3. Gynecologic Medicine Service (8)
  4. Gynecology Disease Management Team (8)
  5. Solid Tumor Oncology Division (8)
  6. Hematologic Malignancies, Division of (4)

More Groups

People
  1. Carol Aghajanian (4)
  2. Claire Friedman (4)
  3. Dmitriy Zamarin (4)
  4. Roisin O'Cearbhaill (4)
  5. Alexia Iasonos (3)
  6. Martee Hensley (3)

More People

Years
  1. 2022 (8)
Publications
  1. Journal of Clinical Oncology (3)
  2. Cancer Research (2)
  3. Annals of Oncology (1)
  4. Gynecologic Oncology (1)
  5. Journal for ImmunoTherapy of Cancer (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. American Association for Cancer Research (2)
  3. Biomed Central Ltd (1)
  4. Elsevier Inc. (1)
  5. Oxford University Press (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Optimization of shared neoantigen vaccine design to increase vaccine potency: From bench to bedside and back
    Meeting Abstract

    Rappaport, A. R.; Palmer, C. D.; Shen, A.; Dominguez, C. X.; Hart, M. G.; Kraemer, L. D.; Koulavouth, S.; Marrali, M.; Jaroslavsky, J. R.; Nganje, C. N.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Lower doses of self-amplifying mRNA drive superior neoantigen-specific CD8 T cell responses in cancer patients versus high doses
    Meeting Abstract

    Palmer, C. D.; Rappaport, A. R.; Hart, M. G.; Kraemer, L. D.; Kounlavouth, S.; Marrali, M.; Jaroslaysky, J. R.; Nganje, C. N.; Shen, A.; Boucher, G. R.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS)
    Meeting Abstract

    Kyi, C. K.; Spira, A.; Carbone, D. P.; Johnson, M. L.; Henick, B. S.; Johnson, B.; Borghaei, H.; Mahipal, A.; Hecht, J. R.; Catenacci, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers
    Journal Article

    Ehmann, S.; Sassine, D.; Straubhar, A. M.; Praiss, A. M.; Aghajanian, C.; Alektiar, K. M.; Broach, V.; Cadoo, K. A.; Jewell, E. L.; Boroujeni, A. M.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC)
    Meeting Abstract

    Grisham, R. N.; Li, K.; Zhou, Q.; Iasonos, A.; Girshman, J.; Shah, P.; Jang, D.; Kyi, C.; Cohen, S. M.; O'Cearbhaill, R. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)
    Meeting Abstract

    Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
    Journal Article

    Schöffski, P.; Tan, D. S. W.; Martín, M.; Ochoa-de-Olza, M.; Sarantopoulos, J.; Carvajal, R. D.; Kyi, C.; Esaki, T.; Prawira, A.; Akerley, W.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save